By Siddhi Mahatole and Puyaan Singh July 31 (Reuters) – AbbVie slightly trimmed its 2026 profit forecast on Friday to account for its planned Apogee Therapeutics acquisition, while topping
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)